Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1184-1187

  Jordan, Karin ^a   Kinitz, Iris ^a   Voigt, Wieland ^a   Behlendorf, Timo ^a   Wolf, Hans Heinrich ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Aprepitant; CINV; Dexamethasone; Granisetron; Multiple day chemotherapy

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; GRANISETRON; IFOSFAMIDE;

ADULT; AGED; ANOREXIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HICCUP; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PSYCHOSIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANISETRON; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MORPHOLINES; NEOPLASMS; RECEPTORS, NEUROKININ-1; SAFETY; TREATMENT OUTCOME;

EID: 64449083250     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.11.046     Document Type: Article

References (10)

1. Kris M.G., Hesketh P.J., Somerfield M.R., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24 18 (2006) 2932-2947
2. Roila F., Hesketh P.J., and Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17 1 (2006) 20-28
3. Jordan K., Schmoll H.J., and Aapro M.S. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61 2 (2007) 162-175
4. Fox S.M., Einhorn L.H., Cox E., Powell N., and Abdy A. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11 12 (1993) 2391-2395
5. Weissbach L. Ondansetron. Lancet 338 8769 (1991) 753-754
6. Einhorn L.H., Brames M.J., Dreicer R., et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15 11 (2007) 1293-1300
7. Forni C., Ferrari S., Loro L., et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 8 2 (2000) 131-133
8. Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 study group. J Clin Oncol 21 22 (2003) 4112-4119
9. Schmoll H.J., Aapro M.S., Poli-Bigelli S., et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17 6 (2006) 1000-1006
10. Durand J.P., Gourmel B., Mir O., and Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 18 4 (2007) 808-809